Ceftaroline vs vancomycin for the treatment of acute pulmonary exacerbations in pediatric patients with cystic fibrosis

Introduction Respiratory infection with methicillin‐resistant Staphylococcus aureus (MRSA) is an increasing complication in cystic fibrosis (CF) that results in accelerated lung function decline and mortality. Vancomycin is considered a first‐line intravenous treatment agent for MRSA associated acut...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric pulmonology 2020-12, Vol.55 (12), p.3337-3342
Main Authors: Branstetter, Joshua, Searcy, Heather, Benner, Kim, Yarbrough, April, Crowder, Carly, Troxler, Brad
Format: Article
Language:English
Subjects:
acute pulmonary exacerbation
Administration, Intravenous
Adolescent
Adult
Anti-Bacterial Agents - therapeutic use
Antibiotics
Ceftaroline
Cephalosporins - therapeutic use
Child
Child, Preschool
Cystic fibrosis
Cystic Fibrosis - drug therapy
Cystic Fibrosis - physiopathology
Female
Forced Expiratory Volume
Humans
Infant
Infant, Newborn
Male
Methicillin-Resistant Staphylococcus aureus
pediatric
Pediatrics
Retrospective Studies
Staphylococcal Infections - drug therapy
Staphylococcal Infections - physiopathology
Staphylococcus infections
vancomycin
Vancomycin - therapeutic use
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Respiratory infection with methicillin‐resistant Staphylococcus aureus (MRSA) is an increasing complication in cystic fibrosis (CF) that results in accelerated lung function decline and mortality. Vancomycin is considered a first‐line intravenous treatment agent for MRSA associated acute pulmonary exacerbations (APEs); however, rates of vancomycin intolerance and resistance have been observed. These factors have led to the exploration of additional treatment options for treating MRSA associated APEs. Methods This is a retrospective chart review conducted at a CF center including patients 0 to 21 years of age with CF admitted for an APE and treated with either vancomycin or ceftaroline between January 2016 and August 2018. The primary endpoint was to determine ceftaroline efficacy compared to vancomycin in the treatment of MRSA associated APEs. Results There were 180 patients included in the study with 90 patients in each antibiotic group. Admission to discharge forced expiratory volume in 1 second (FEV1) improved in the ceftaroline (66.5% vs 81.1%; P 
ISSN:8755-6863
1099-0496
DOI:10.1002/ppul.25029